A Boston-based biopharmaceutical company is revolutionizing the weight-loss drug industry. Syntis Bio has created a daily ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

after the drugmaker reported positive results from a late-stage trial of a GLP-1 treatment for Type 2 diabetes and obesity in pill form. The last time the stock rose as much was June 29 ...